Efficacy of Iguratimod on Mineral and Bone Disorders After Kidney Transplantation: a Preliminary Study

Overview

Journal Ren Fail

Publisher Informa Healthcare

Date 2023 Oct 31

PMID 37905940

Authors

Li Sun

Jun Tao

Zhijian Han

Hao Chen

Zhengkai Huang

Zijie Wang

Shuang Fei

Chuanjian Suo

Xiaobing Ju

Ruoyun Tan

Min Gu

Affiliations

Soon will be listed here.

Abstract

Background: Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs).

Methods: A analysis was conducted among the subjects in our previous randomized clinical trial (NCT02839941). Forty-three KTRs completing bone metabolism 52 weeks after enrollment were selected for this analysis, among whom 27 patients received VC examinations. In the iguratimod group, iguratimod (25 mg twice daily) was added adjuvant to the traditional triple regimen. At the 52-week follow-up, the following parameters were assessed: serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP), osteocalcin, type I collagen N-terminal peptide (NTx), type I collagen C-terminal peptide (CTx), bone mineral density (BMD) of the femoral neck and lumbar spine, coronary artery calcification (CAC) and thoracic aortic calcification (TAC). Bone metabolic and VC indices were compared between the two groups using the independent samples t test and Wilcoxon nonparametric test.

Results: At 52 weeks after enrollment, the iguratimod group had lower osteocalcin ( = 0.010), BALP ( = 0.015), NTx ( = 0.007), CTx ( = 0.012), CAC ( = 0.080) and TAC scores ( = 0.036) than the control group. There was no significant difference in serum calcium, phosphorus, 25-hydroxyvitamin D, iPTH and BMD between the groups. Iguratimod could reduce bone turnover markers (BTMs) at both high and low iPTH levels. The adverse effect of iguratimod was mild and tolerable.

Conclusion: Iguratimod is safe, can reduce BTMs and may could attenuate VC in the first year after KT.

Citing Articles

A systematic review and meta-analysis of the efficacy and safety of iguratimod in the treatment of inflammatory arthritis and degenerative arthritis.

Long Z, Zeng L, Yang K, Chen J, Luo Y, Dai C Front Pharmacol. 2024; 15:1440584.

PMID: 39449973 PMC: 11499590. DOI: 10.3389/fphar.2024.1440584.

Individualizing the lifesaving journey for calciphylaxis: addressing rapidly progressive attacks with multidimensional and AI research for regenerative medicine.

Wang N, Angioi A, Hanset N, Ye X, Lu S, Zhu Y Ren Fail. 2024; 46(2):2392846.

PMID: 39234636 PMC: 11378655. DOI: 10.1080/0886022X.2024.2392846.

References

Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, Lopez-Ongil S . RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009; 104(9):1041-8. DOI: 10.1161/CIRCRESAHA.108.189001. View

Ishikawa K, Ishikawa J . Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients. Mod Rheumatol. 2018; 29(3):418-429. DOI: 10.1080/14397595.2018.1481565. View

Wang X, Ma C, Li P, Zhao F, Bi L . Effects of iguratimod on the levels of circulating regulators of bone remodeling and bone remodeling markers in patients with rheumatoid arthritis. Clin Rheumatol. 2017; 36(6):1369-1377. DOI: 10.1007/s10067-017-3668-8. View

Seyahi N, Cebi D, Altiparmak M, Akman C, Ataman R, Pekmezci S . Progression of coronary artery calcification in renal transplant recipients. Nephrol Dial Transplant. 2011; 27(5):2101-7. DOI: 10.1093/ndt/gfr558. View

Li C, Ma Z, Jian L, Wang X, Sun L, Liu X . Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways. Int Immunopharmacol. 2020; 90:107219. DOI: 10.1016/j.intimp.2020.107219. View

Tao J, Sun L, Wang Z, Chen H, Han Z, Zhang H . Efficacy and Safety of Iguratimod Supplement to the Standard Immunosuppressive Regimen in Highly Mismatched Renal Transplant Recipients: A Pilot Study. Front Immunol. 2021; 12:738392. PMC: 8650225. DOI: 10.3389/fimmu.2021.738392. View

Kuriyama K, Higuchi C, Tanaka K, Yoshikawa H, Itoh K . A novel anti-rheumatic drug, T-614, stimulates osteoblastic differentiation in vitro and bone morphogenetic protein-2-induced bone formation in vivo. Biochem Biophys Res Commun. 2002; 299(5):903-9. DOI: 10.1016/s0006-291x(02)02754-7. View

Palmer S, Chung E, McGregor D, Bachmann F, Strippoli G . Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev. 2019; 10:CD005015. PMC: 6803293. DOI: 10.1002/14651858.CD005015.pub4. View

Kan S, Ning G, Chen L, Zhou Y, Sun J, Feng S . Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis. Medicine (Baltimore). 2016; 95(5):e2679. PMC: 4748922. DOI: 10.1097/MD.0000000000002679. View

10.

Thongprayoon C, Acharya P, Aeddula N, Torres-Ortiz A, Bathini T, Sharma K . Effects of denosumab on bone metabolism and bone mineral density in kidney transplant patients: a systematic review and meta-analysis. Arch Osteoporos. 2019; 14(1):35. DOI: 10.1007/s11657-019-0587-0. View

11.

Wolf M, Weir M, Kopyt N, Mannon R, Visger J, Deng H . A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation. Transplantation. 2015; 100(1):184-93. PMC: 4683035. DOI: 10.1097/TP.0000000000000823. View

12.

Ulsamer A, Ortuno M, Ruiz S, Susperregui A, Osses N, Rosa J . BMP-2 induces Osterix expression through up-regulation of Dlx5 and its phosphorylation by p38. J Biol Chem. 2007; 283(7):3816-26. DOI: 10.1074/jbc.M704724200. View

13.

Sakaguchi Y, Hamano T, Wada A, Hoshino J, Masakane I . Magnesium and Risk of Hip Fracture among Patients Undergoing Hemodialysis. J Am Soc Nephrol. 2017; 29(3):991-999. PMC: 5827604. DOI: 10.1681/ASN.2017080849. View

14.

Canalis E, Mazziotti G, Giustina A, Bilezikian J . Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007; 18(10):1319-28. DOI: 10.1007/s00198-007-0394-0. View

15.

Farmer C, Hampson G, Abbs I, Hilton R, Koffman C, Fogelman I . Late low-dose steroid withdrawal in renal transplant recipients increases bone formation and bone mineral density. Am J Transplant. 2006; 6(12):2929-36. DOI: 10.1111/j.1600-6143.2006.01557.x. View

16.

Jiang H, Gao H, Wang Q, Wang M, Wu B . Molecular mechanisms and clinical application of Iguratimod: A review. Biomed Pharmacother. 2020; 122:109704. DOI: 10.1016/j.biopha.2019.109704. View

17.

Evenepoel P, Claes K, Meijers B, Laurent M, Bammens B, Naesens M . Natural history of mineral metabolism, bone turnover and bone mineral density in de novo renal transplant recipients treated with a steroid minimization immunosuppressive protocol. Nephrol Dial Transplant. 2018; 35(4):697-705. DOI: 10.1093/ndt/gfy306. View

18.

Cianciolo G, Capelli I, Angelini M, Valentini C, Baraldi O, Scolari M . Importance of vascular calcification in kidney transplant recipients. Am J Nephrol. 2014; 39(5):418-26. DOI: 10.1159/000362492. View

19.

Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T . Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2012; 23(3):430-9. DOI: 10.1007/s10165-012-0724-8. View

20.

Song J, Liu H, Zhu Q, Miao Y, Wang F, Yang F . T-614 Promotes Osteoblastic Cell Differentiation by Increasing Dlx5 Expression and Regulating the Activation of p38 and NF-B. Biomed Res Int. 2018; 2018:4901591. PMC: 5836304. DOI: 10.1155/2018/4901591. View